Gsa Capital Partners LLP Nuvation Bio Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 1,627,122 shares of NUVB stock, worth $6.02 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
1,627,122
Previous 661,052
146.14%
Holding current value
$6.02 Million
Previous $1.16 Million
172.83%
% of portfolio
0.22%
Previous 0.11%
Shares
11 transactions
Others Institutions Holding NUVB
# of Institutions
196Shares Held
168MCall Options Held
2.31MPut Options Held
221K-
Decheng Capital LLC Menlo Park, CA26MShares$96 Million12.78% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$60.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.9MShares$58.8 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA11MShares$40.9 Million46.36% of portfolio
-
Laurion Capital Management LP New York, NY10.2MShares$37.9 Million0.37% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $804M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...